Britain and America have concluded a major trade agreement that will ensure zero tariffs on British drug exports going into the US market.
Agreement Details of the Accord
As part of the deal, the UK has agreed to raise funding on drugs through the NHS. This move guarantees that import taxes on these crucial products will remain at zero for a period of 36 months.
This agreement is in response to earlier statements to hike duties on branded pharmaceutical imports, with increases floated as high as double the cost.
"This arrangement between the UK bolsters the international landscape for cutting-edge drugs and introduces much-needed balance to American-British drug exports," a release declared.
Commercial Importance
Pharmaceuticals represent one of the Britain's most significant export categories to the US, which is by far the biggest buyer for leading UK drugmakers.
Export figures indicate that in the year to the end of last September, the UK shipped medicines worth £11.1bn to the US. This amount made up 17.4% of all goods exports in that period.
"This agreement protects employment, boosts investment and sets the stage for the UK to establish itself as a global hub for biotech and pharma," a minister commented.
Detailed British Pledges
The pact involves several notable commitments from the British government:
- Higher Cost Ceiling: The UK will increase the affordability limit at which it deems new therapies to be prohibitively costly by twenty-five percent.
- Increased NHS Spending: There is a target to increase total NHS spending on treatments from 0.3 percent of the national economy to 0.6 percent over the next decade.
- Refund Ceiling: The percentage manufacturers must pay back to the NHS to stay within budget will be limited at fifteen percent. Previously, refunds were more than 20%.
Recent Tensions
The deal takes place against a long-running tension between the drug companies and the UK government over spending levels and NHS adoption.
This friction were heightened by assertions that US consumers were charged a premium for the equivalent treatments than people in the Britain and the EU.
Recently, several major pharmaceutical investments in the UK have been halted or scrapped, while substantial expansions have been announced toward US facilities.
One official acknowledged that the NHS must spend more on treatments, noting that its budget allocation on drugs had shrunk as a percentage of its total funding over the last ten years.
